Emerging fungal resistance

Clinics in Laboratory Medicine

Volumn 24, Issue 3, 2004, Pages 721-735

  Baddley, John W ^a,b   Moser, Stephen A ^c  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POLYENE ANTIBIOTIC AGENT; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; DRUG MECHANISM; DRUG TARGETING; FUNGAL GENE; FUNGAL STRAIN; FUNGAL VIRULENCE; FUSARIUM; GENE TARGETING; HUMAN; MOLECULAR DYNAMICS; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCEDOSPORIUM; TRICHOSPORON;

ANTIFUNGAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, FUNGAL; HUMANS; MYCOSES;

EID: 8444232765     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.05.003     Document Type: Review

References (97)

1. Groll A., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., Huebner K. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 33:1996;23-32
2. Marr K., Carter R., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 34:2002;909-917
3. Pfaller M.A., Diekema D. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol. 40:(10):2002;3551-3557
4. Walsh T.J., Groll A., Hiemenez J., Fleming R., Roilides E., Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 10:(Suppl 1):2004;48-66
5. Husain S., Alexander B., Munoz P., Avery R., Houston S., Pruett T., et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 37:2003;221-229
6. Perea S., Patterson T.F. Antifungal resistance in pathogenic fungi. Clin Infect Dis. 35:2002;1073-1080
7. Cuenca-Estrella M., Ruiz-Diez B., Martinez-Suarez J.V., Monzon A., Rodriguez-Tudela J.L. Comparative in-vitro activity of voriconazole (UK 109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 43:(1):1999;149-151
8. Kontoyianis D.P., Lewis R. Antifungal drug resistance of pathogenic fungi. Lancet. 359:2002;1135-1144
9. Yoon S., Vasquez J., Steffan P., Sobel J.D., Akins R. High-frequency in vitro switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother. 43:1999;836-845
10. White T.C., Marr K., Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 11:1998;382-402
11. Loeffler J., Stevens D.A. Antifungal drug resistance. Clin Infect Dis. 36:(Suppl 1):2003;S31-S41
12. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard - 2nd edition. 2002;NCCLS, Wayne (PA). M27-A2
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved Standard - 1st edition. 2002;NCCLS, Wayne (PA). M38-A1
14. Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 24:(2):1997;235-247
15. Gallis H.A., Drew R.H., Pickard W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 12:1990;308-329
16. Ghannoum M.A., Rice L. Antifungal agents: mode of actions, mechanism of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 12:1999;501-517
17. Vanden Bossche H., Willemsens G., Marichal P. Anti-Candida drugs - the biochemical basis for their activity. CRC Crit Rev Microbiol. 15:1978;57-72
18. Walsh T.J., Melcher G., Rinaldi M. Trichosporon beigelii [asahii]: an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 28:1990;1616-1622
19. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 49:(Suppl 1):2002;7-10
20. Young L.Y., Hull C., Heitman J. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother. 47:(9):2003;2717-2724
21. Peyron F., Favel A., Calaf R., Michel-Nguyen A., Bonaly R., Coulon J. Sterol and fatty acid composition of Candida lusitaniae clinical isolates. Antimicrob Agents Chemother. 46:(2):2002;531-533
22. Seo K., Akiyoshi H., Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol. 43:1999;1017-1025
23. Como J.A., Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 330:(4):1994;263-272
24. White T.C., Holleman S., Dy F., Mirels L., Stevens D.A. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 46:(6):2002;1704-1713
25. Pinjon E., Moran G., Jackson C.J., Kelly S.L., Sanglard D., Coleman D.C., et al. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother. 47:(8):2003;2424-2437
26. Barchiesi F., Calabrese D., Sanglard D., Falconi D.I., Francesco L., Caselli G., et al. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother. 44:2000;1578-1584
27. Posteraro B., Sanguinetti M., Sanglard D., La Sorda M., Boccia S., Romano L., et al. Identification and characterization of a Cryptococcus neoformans ATP Binding Cassette (ABC) transporter-encoding gene, CnDR1, involved in the resistance to fluconazole. Mol Microbiol. 47:2003;357-371
28. Slaven J., Anderson M., Sanglard D., Dixon G., Bille J., Roverst I., et al. Induced expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in response to itraconazole. Fungal Genet Biol. 36:2002;199-206
29. Sanglard D., Kuchler K., Ischer F., Pagani J., Monod M., Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 39:1995;2378-2386
30. White T.C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother. 41:1997;1482-1487
31. Vanden Bossche H., Marichal P., Gorrens J., Bellens D., Moereels H., Janssen P.A.J. Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans. 28:1990;56-59
32. Lamb D.C., Corran A., Baldwin B.C., Kwon-Chung J., Kelly S.L. Resistant P450A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett. 368:1995;326-330
33. Orozco A.S., Higginbotham L.M., Hitchcock C.A., Parkinson T., Falconer D., Ibrahim A.S., et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 42:(10):1998;2645-2649
34. Sanglard D., Ischer F., Koymans L., Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 42:1998;241-253
35. Karyotakis N.C., Anaissie E.J., Hachem R., Dignani M.C., Samonis G. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis. 168:1993;1311-1313
36. Young L.Y., Hull C., Heitman J. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother. 47:(9):2003;2717-2724
37. Hector R.F. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev. 6:1993;1-21
38. Deresinski S.C., Stevens D.A. Caspofungin. Clin Infect Dis. 36:2003;1445-1457
39. De Bono M., Gordee R.S. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 48:1994;471-477
40. Vasquez J., Lynch M., Boikov D., Sobel J.D. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother. 41:1997;1612-1614
41. Douglas C. Fungal beta (1,3)-D-glucan synthesis. Med Mycol. 39:(Suppl 1):2001;55-66
42. Douglas C., Foor F., Marrinan J., Morin N., Nielsen J., Dahl A., et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A. 91:(26):1994;12907-12911
43. Douglas C., Marrinan J., Li W., Kurtz M. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol. 176:(18):1994;5686-5696
44. Bouffard F., Zambias R., Dropinski J., Balkovec J., Hammond M., Abruzzo G.K., et al. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem. 37:(2):1994;222-225
45. Douglas C., D'Ippolito J., Shei G., Meinz M., Onishi J., Marrinan J., et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 41:(11):1997;2471-2479
46. Schuetzer-Muehlbauer M., Willinger B., Krapf G., Enzinger S., Presterl E., Kuchler K. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol. 48:(1):2003;225-235
47. Polak A., Sholer H. Mode of action of 5-fluorocytosine in the treatment of cryptococcal and candida mycoses. Ann Intern Med. 21:1975;113-130
48. Fass R.J., Perkins R.L. 5-fluorocytosine in the treatment of cryptococcal and candida mycoses. Ann Intern Med. 74:1971;535-539
49. Vermes A., Guchelaar H., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity, and drug interactions. J Antimicrob Chemother. 46:2000;171-179
50. Diasio R., Bennett J.E., Myers C. Mode of action of 5-fluorocytosine. Biochem Pharmacol. 27:1978;703-707
51. Vanden Bossche H., Warnock D.W., Dupont B., Kerridge D., Sen Gupta S., Improvisi L., et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol. 32:(Suppl 1):1994;189-202
52. Fasoli M., Kerridge D. Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species. Ann N Y Acad Sci. 544:1988;260-263
53. Polak A. 5-fluorocytosine - current status with special references to mode of action and drug resistance. Contrib Microbiol Immunol. 4:1977;158-167
54. Normark S., Schonebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother. 2:1973;114-121
55. Polak A., Scholer H.J. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 21:1975;113-130
56. Rangel-Frausto M.S., Wiblin T., Blumberg H.M., Saiman L., Patterson J., Rinaldi M.G., et al. National epidemiology of mycoses survey (NEMIS): variations in rates of blood stream infections due to Candida species in seven surgical intensive care units. Clin Infect Dis. 29:(2):1999;253-258
57. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 29:1999;239-244
58. Blumberg H.M., Jarvis W.R., Soucie J.M., Edwards J.E. Jr., Patterson J.E., Pfaller M.A., et al. Risk factors for candidal blood stream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis. 33:(2):2001;177-186
59. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., Diekema D. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol. 41:(5):2003;2176-2179
60. Pfaller M.A., Diekema D. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 10:(Suppl 1):2004;11-23
61. Makarova N.U., Pokrowsky V.V., Kravchenko A.V., Serebrovskaya L.V., James M.J., McNeil M.M., et al. Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility. J Clin Microbiol. 41:(5):2003;1833-1837
62. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 325:1991;1274-1277
63. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 47:(10):2003;3149-3154
64. Dismukes W.E. Management of cryptococcosis. Clin Infect Dis. 17:(Suppl 2):1993;S507-S512
65. Brandt M.E., Pfaller M.A., Hajjeh R.A. Trends in antifungal drug susceptibility in Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother. 45:1998;3065-3069
66. Perfect J.R., Cox G.M. Drug resistance in Cryptococcus neoformans. Drug Resistance Updates. 2:1999;259-269
67. Witt M., Lewis R., Larsen R.A., Milefchik E.N., Leal M.A.E., Haubrich R.H., et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis. 22:1996;322-328
68. Armengou A., Porcar C., Mascaro J., Garcia-Gragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 23:1996;1337-1338
69. Aller A.I., Martin-Mazuelos E., Lozano F., Gomez-Mateos J., Steele-Moore L., Holloway W.J., et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother. 44:2000;1544-1548
70. Walsh T.J., Lee J.W., Melcher G.P., Navarro E., Bacher J., Callender D., et al. Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis. 166:1992;121-133
71. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine. 79:2000;250-260
72. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 32:2001;358-366
73. Moore C.B., Sayers N., Mosquera J., Slaven J., Denning D.W. Antifungal drug resistance in Aspergillus. J Infect. 41:2004;203-220
74. Denning D.W., Radford S.A., Oakley K.L., Hall J., Johnson E.M., Warnock D.W. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 40:1997;401-414
75. Arikan S.A., Lozano-Chiu M., Paetznick V., Nagia A., Rex J.H. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 37:1999;3946-3951
76. Sutton D.A., Sanche S.E., Revankar S.G., Fothergill A.W., Rinaldi M.G. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison with voriconazole. J Clin Microbiol. 37:(7):1999;2343-2345
77. Baddley J.W., Pappas P.G., Smith A.C., Moser S.A. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol. 41:2003;5525-5529
78. Iwen P.C., Rupp M.E., Langnas A.N., Reed E.C., Hinrichs S.H. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis. 26:1998;1092-1097
79. Tritz D.M., Woods G.L. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts. Clin Infect Dis. 16:1993;118-122
80. Dannaoui E., Borel E., Persat F., Piens M.A., Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol. 49:2000;601-606
81. Dannaoui E., Persat F., Monier M.F., Borel E., Piens M.A., Picot S. In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother. 44:1999;553-555
82. Dannaoui E., Borel E., Monier M.F., Piens M.A., Picot S., Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 47:(3):2001;333-340
83. Warrius A., Weemaes C.M., Verweij P.E. Multidrug resistance in Aspergillus fumigatus. N Engl J Med. 26:2002;2173-2174
84. Dannaoui E., Borel E., Persat F., Monier M.F., Piens M.A. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. J Med Microbiol. 48:(12):1999;1087-1093
85. Mosquera J., Denning D.W. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 46:2002;556-557
86. Manavathu E.K., Cutright J.L., Loebenberg D., Chandrasekar P.H. A comparative study of the in-vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCG 56592). J Antimicrob Chemother. 46:2000;229-234
87. Anaissie E., Kantarjian H., Ro J., Hopfer R., Rolston K., Fainstein V., et al. The emerging role of Fusarium infections in patients with cancer. Medicine. 67:(2):1988;77-83
88. Boutati E.I., Annaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood. 90:1997;999-1008
89. Vartivarian S.E., Annaissie E.J., Bodey G.P. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis. 17:(Suppl 2):1993;S487-S491
90. Sun Q.N., Fothergill A.W., McCarthy D.I., Rinaldi M.G., Graybill J.R. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 46:2002;1581-1582
91. Anaissie E.J., Hachem R., Legrand C., Legenne P., Nelson P., Bodey G.P. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis. 165:1992;1155-1157
92. Walsh T.J., Finberg R.W., Arndt C., Hiemenez J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 340:(10):1999;764-771
93. Consigny S., Dhedin N., Datry A., Choquet S., Leblond V., Chosidow O. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis. 37:2003;311-313
94. Espinel-Ingroff A. Comparison of in-vitro activities of new triazole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 36:1998;2950-2956
95. Revankar S.G., Patterson J.E., Sutton D.A., Pullen R., Rinaldi M.G. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis. 34:(4):2002;467-476
96. Walsh T.J., Peter J., McGough D.A., Fothergill A.W., Rinaldi M.G., Pizzo P.A. Activity of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother. 39:(6):1995;1361-1364
97. Walsh T.J., Lustar I., Driscoll T., Dupont B., Roden M., Ghahramani P., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr Infect Dis. 21:(3):2002;240-248